
- Volume 0 0
Rebetol Oral Solution
Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.
Articles in this issue
almost 22 years ago
Interface Speeds Up Prescription Fillingalmost 22 years ago
New Technologies Top Surveyalmost 22 years ago
Partnership Addresses Packaging Solutionsalmost 22 years ago
PDX Software Gets High Marksalmost 22 years ago
Polar Powder Cold Pak with Magnetic Therapyalmost 22 years ago
Seal•ONalmost 22 years ago
SaltAire Sinus Reliefalmost 22 years ago
Zim's Crack Creme Hand Sanitizeralmost 22 years ago
CoroWise Plant Sterolsalmost 22 years ago
CulturelleNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.




































































































































































































